8 / 21
Page 42
Notes:
conferenceseries
.com
Volume 7, Issue 4 (Suppl)
J Clin Exp Pathol, an open access journal
ISSN: 2161-0681
Euro Pathology 2017
August 02-03, 2017
13
th
EUROPEAN PATHOLOGY CONGRESS
August 02-03, 2017 Milan, Italy
Mesenchymal epithelial transitionmarker and androgen receptor in estrogen receptor negative breast cancer
Dalia M Abouelfadl
National Research Institute, Egypt
Introduction:
Breast cancers are heterogeneous in their morphology, clinical course and response to therapy. New therapeutic
targets are needed in breast cancer. The Met tyrosine kinase receptor activates cell proliferation, survival, invasion and
angiogenesis and has found a strong relationship between high HGF/Met signaling and tumor progression. The biologic roles
of androgen receptors (AR) in the breast are incompletely understood since it is unclear whether the effects of androgens on
breast cells are predominantly proliferative or anti-proliferative.
Aim:
The aimof this study is to determine the prognostic value of mesenchymal–epithelial transition (MET) and AR expression
in breast cancer patients with ER negative receptor.
Method:
Histologic sections from 60 cases of ER negative breast cancer including different subtypes and grades of breast
cancer were evaluated using immunohistochemistry with androgen and Met then evaluated compared to ER, PR, HER-2,
using a standard avidin–biotin–peroxidase system.
Results:
Out of the 60 breast cancers, 54 (90%) are positive for AR and 52 (86%) are positive for Met. There was a significant
positive correlation between AR with tumor type, multicentricity and HER2 (P<0.005). Met scores were significantly increased
in patients nodal stage, DCIS and HER2 (P<0.005).
Conclusions:
There is a significant correlation between the Met and AR scores and the clinicopathological prognostic
parameters. The levels of AR and Met expression were relatively high as most studies stated. The activation of Met signaling
pathway plays an important role in tumorgenesis of breast cancers and the patients might benefit from drug therapy targeting
Met in cases showing expression of such receptor.
Biography
Dalia MAbouelfadl has completed her MD at Cairo University and Postdoctoral studies at Westminster University School of Biomedical Sciences, London, UK. She
is a member of Pathology department of Medical Division of National Research Center, a premier research organization. She has published more than 10 papers
in reputed journals.
fadlawy2004@yahoo.comDalia M Abouelfadl, J Clin Exp Pathol 2017, 7:4(Suppl)
DOI: 10.4172/2161-0681-C1-037